NDAORALTABLETPriority Review
Approved
Apr 2017
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
5
Data completeness
5/8 — Partial
Priority Review
ROXYBOND (oxycodone hydrochloride) by Bayer is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. First approved in 2017.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROXYBOND is an oral tablet formulation of oxycodone hydrochloride, a mu-opioid receptor agonist approved in 2017 for pain management. It works by binding to opioid receptors in the central nervous system to provide analgesia without a ceiling effect on dose escalation. The drug is indicated for patients requiring opioid analgesics, with dosing titrated to balance efficacy against respiratory and CNS depression.
$0.771MPart D
LOE ApproachingDeclining
1.8 years to LOEProduct is in final patent-protected years with minimal current claims volume, signaling a contracting team and shift toward LOE planning and transition strategies.
Mechanism of Action
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users
Started Aug 2026
60 enrolled
Healthy
A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain
Started Jun 2012
410 enrolled
Chronic PainLow Back PainAnalgesia
Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001
Started Oct 2011
23 enrolled
Pain
Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain
Started Dec 2010
395 enrolled
Chronic Noncancer Pain
Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
Started Nov 2010
155 enrolled
Pain
Worked on ROXYBOND at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.